Navigation Links
Tengion Reports Fourth Quarter and Full Year 2011 Financial Results
Date:3/26/2012

an be accessed from the Investors section of the Company's website or directly at http://edge.media-server.com/m/p/o4v89uyi/lan/en. The webcast will also be archived on the website.

About TengionTengion, a clinical-stage regenerative medicine company, is focused on discovering, developing, manufacturing and commercializing a range of neo-organs, or products composed of living cells, with or without synthetic or natural materials, implanted or injected into the body to engraft into, regenerate, or replace a damaged tissue or organ.  Using its Organ Regeneration Platform™, the Company creates neo-organs using a patient's own cells, or autologous cells.  Tengion's proprietary product candidates harness the intrinsic regenerative pathways of the body to regenerate a range of native-like organs and tissues.  The Company's product candidates are intended to delay or eliminate the need for chronic disease therapies, organ transplantation, and the administration of anti-rejection medications.  An initial clinical trial is ongoing for the Company's lead product candidate, the Neo-Urinary Conduit™, an autologous implant that is intended to catalyze regeneration of native-like bladder tissue for bladder cancer patients requiring a urinary diversion following bladder removal. The Company's lead preclinical candidate is the Neo-Kidney Augment™, which is designed to prevent or delay dialysis by increasing renal function in patients with advanced chronic kidney disease. Tengion has worldwide rights to its product candidates.

Forward-Looking StatementsCertain statements set forth above may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to the Company's: (i) plans
'/>"/>

SOURCE Tengion, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Tengion Launches Second Phase 2 Clinical Trial of Regenerated Human Organ
2. Tengion Launches Third Phase 2 Clinical Trial of Regenerated Human Bladder
3. Preclinical Data Demonstrate Ability to Regenerate an Entire Bladder With Tengion Neo-Bladder Replacement(TM)
4. Tengion Scientists Publish Key Preclinical Findings Demonstrating the Benefits of Organ Regeneration Vs. Repair
5. Tengion Appoints Sunita B. Sheth, M.D., Chief Medical Officer
6. Tengion Presents New Data Demonstrating Functional Regeneration in a Diabetic Chronic Kidney Failure Model at the International Society for Cellular Therapy
7. Tengion Announces First Implantation of Neo-Urinary Conduit™ in Initial Clinical Trial in Patients with Bladder Cancer
8. Tengion Reviews Pipeline Progress at First Analyst and Investor Meeting; Strategic & Clinical Updates Provided for Regenerative Medicine Programs
9. Tengion Provides Business Update and Reports Third Quarter 2010 Financial Results
10. Tengion Advances Clinical Trial for Neo-Urinary Conduit™ in Bladder Cancer Patients
11. Tengion Presents New Data in Nine Posters and Two Oral Presentations at TERMIS North America Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 11, 2014  Australian drug delivery company, Phosphagenics Limited ... raised A$19.3 million via a placement of A$16.3 million ... the U.S., Asia and ... share purchase plan (SPP) to be offered to existing ... in two tranches. "This capital raising positions ...
(Date:7/11/2014)... York , July 11, 2014 ... Transparency Market Research "Endoscopy Devices Market (Endoscopes, Endoscopic Operative ... Share, Growth, Trends and Forecast, 2013-2019" the global endoscopy ... 2012 and is expected to grow at a CAGR ... estimated value of USD 36.9 billion in 2019. ...
(Date:7/11/2014)... , July 11, 2014  Veran Medical ... announced today the positive, cost-effective final results ... SPiNPerc™ procedure. The SPiNPerc endobronchial percutaneous biopsy ... percutaneous approach to biopsy when a traditional ... and physicians experience positive financial outcomes when ...
Breaking Medicine Technology:Phosphagenics' A$19.3 million Capital Raising 2Phosphagenics' A$19.3 million Capital Raising 3Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 2Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 3Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 4Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 5Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 6Veran Medical Publishes Lung Cancer Patient Management Study 2
... To Be Presented in a Poster Session at the ... -SAN FRANCISCO, March 6 Galderma Laboratories, L.P. today ... of plaque psoriasis using Clobex (R) (clobetasol propionate) ... 3mcg/g. The results of an interim analysis of ...
... Germany, March 6 B-R-A-H-M-S,Aktiengesellschaft today announced it ... Drug Administration (FDA) to market its patented B-R-A-H-M-S,MR-proANP ... Natriuretic Peptide (ANP) is predominantly produced in the ... natriuretic peptides in the,circulation. ANP is involved in ...
Cached Medicine Technology:Galderma Announces Interim Data Relating to Sequential Treatment Regimen of Clobex(R) Spray Followed by Vectical(TM) Ointment in Managing Plaque Psoriasis 2Galderma Announces Interim Data Relating to Sequential Treatment Regimen of Clobex(R) Spray Followed by Vectical(TM) Ointment in Managing Plaque Psoriasis 3Galderma Announces Interim Data Relating to Sequential Treatment Regimen of Clobex(R) Spray Followed by Vectical(TM) Ointment in Managing Plaque Psoriasis 4FDA Submission of B-R-A-H-M-S MR-proANP Kryptor 2
(Date:7/14/2014)... Rock Hill, SC (PRWEB) July 14, 2014 ... vegetables, but a study by the School of Public ... fruit and vegetable consumption had a near-zero effect on weight ... foods must be combine with some form of portion ... is a method of monitoring portions and controlling how much ...
(Date:7/14/2014)... Sometimes, thinking “inside the box” can be ... first product release, Joyboxx™ - The world’s only hygienic ... , Inventor and CEO, Deborah Semer began designing a ... solution for their ‘toys’ after she realized no such ... , Semer met 30-year industry veteran Phyllis Heppenstall, the ...
(Date:7/14/2014)... EurekaMag.com has newly published results of 64,900 ... disease that ranges in severity from a mild ... illness that attacks the liver. An estimated 3.2 million ... virus infection of which approximately 80% of people develop ... all studies on Hepatitis C , the Life, Earth ...
(Date:7/14/2014)... (PRWEB) July 14, 2014 "Medical devices, ... one of us. The Tri-Valley is a star when ... based in the region are working on amazing products ... the face of medicine," according to Dale Kaye CEO ... To showcase some of the brilliant minds and businesses ...
(Date:7/14/2014)... WI (PRWEB) July 14, 2014 Doctor ... announced the launch of their new company website. The ... valuable free information on chiropractic marketing. It's also a ... that Inception has to offer. , When contacted at ... the newest version of our main website. Our site ...
Breaking Medicine News(10 mins):Health News:Increase Vegetable Consumption Has Zero Effect on Weight Loss – Portion Control is Recommended by Experts 2Health News:Increase Vegetable Consumption Has Zero Effect on Weight Loss – Portion Control is Recommended by Experts 3Health News:Passionate Playground launches Joyboxx 2Health News:Passionate Playground launches Joyboxx 3Health News:EurekaMag.com Publishes 64,900 New Studies on Hepatitis C 2Health News:Believing in the Possible – Innovation Tri-Valley’s Sixth Innovation Forum Examines the Tri-Valley’s Wealth of Innovators 2Health News:Believing in the Possible – Innovation Tri-Valley’s Sixth Innovation Forum Examines the Tri-Valley’s Wealth of Innovators 3Health News:Believing in the Possible – Innovation Tri-Valley’s Sixth Innovation Forum Examines the Tri-Valley’s Wealth of Innovators 4Health News:Doctor Mike Hamilton From Inception Chiropractic Websites Announces the Launch of Their New Website 2
... (CDC)’s Morbidity and Mortality Weekly Report, West Virginia has a ... the U.S. Virgin Islands has the lowest. ... data collected through the Behavioral Risk Factor Surveillance System, a ... health departments. ,Levels of coronary heart disease, ...
... including four doctors have been accused of cheating insurance ... involved in giving allergy shots to many// patients without ... ,Patients were also not informed about the risk factors ... for testing procedures were not sent to the lab ...
... Genetic factors play an important role in the ... University School of Medicine in St. Louis.// ... genetic variations can influence smoking behaviors and contribute ... ,Scientists suggest that these smoking-related genes may ...
... to make many plastics found in food storage containers ... according to a recent study by Yale School of ... Taylor, M.D., associate professor in the Department of Obstetrics, ... study shows that BPA changes the expression of key ...
... risk of rash, leading to treatment discontinuation or interruption//, ... research published in the January edition of HIV Medicine. ... once daily were more likely to experience liver complications ... For these reasons, the authors conclude that once-daily nevirapine ...
... consumers not to purchase, or use, Wild Kitty Cat Food ... monitoring activities, FDA collected and analyzed a sample of frozen ... product. Cats and other pets consuming this food may become ... if they handle or ingest this cat food, touch pets ...
Cached Medicine News:Health News:Genes for Nicotine Dependence Identified 2Health News:Genes for Nicotine Dependence Identified 3Health News:Genes for Nicotine Dependence Identified 4Health News:Once-daily Nevirapine Has More Side-effects Than Twice-daily Dose 2Health News:Once-daily Nevirapine Has More Side-effects Than Twice-daily Dose 3Health News:Consumers Warned of Using Cat Food Due to Salmonella Contamination 2
High resolution, multi-frequency, HST version of the UST-987-7.5. Provides even greater image detail, better resolution, and penetration....
... Penetration Steered Linear Peripheral Vascular transducer, with ... MHz. It is our newest vascular ... 4 different settings to optimize imaging of ... color and Doppler sensitivity of this transducer ...
... Super High Density, multi-frequency, linear ... "twist on the UST-5536, this ... it sweeps horizontally as well ... axis so that target lesions ...
... The UST-MC11-8731 is a perfect alternative ... are used to seeing more of a ... of the transducer in the hand., This ... shaped convex intraoperative transducer. The UST-MC11-8731 nestles ...
Medicine Products: